In particular, the combination of targeted and controlled-release polymer nanotechnologies has recently resulted in the clinical development of BIND-014, a promising targeted Docetaxel-loaded nanoprototype, which can be validated for use in the prostate cancer therapy.
However, to date, no self-report instrument to assess NA to immunosuppressive therapy has been validated for use in Brazilian Portuguese-speaking patients.
The model reported here has been estimated and validated for use in predicting recurrence-free survival before adjuvant systemic therapy.
We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.
Using this system, newly identified genes can be rapidly validated for their roles in tumor formation, progression, maintenance, and resistance to therapy.
Where the MammaPrint assay was designed for assessing prognosis in breast cancers, the commercially available Oncotype DX gene assay [ 4] was originally designed and extensively validated for predicting response to tamoxifen therapy in ER-positive breast cancer patients.
SWD was originally developed in the context of postmenopausal hormone-replacement therapy decisions [ 46], and has been validated for use with people with depression [ 59].
Corticosteroids, both intra- and extraocular, have long been used to treat edema with RVO, and the SCORE study results validated this therapy for edema in CRVO while confirming grid laser photocoagulation as superior treatment for edema in BRVO [ 6, 7].
Recently, antiangiogenic therapy, often in combination with conventional chemotherapy, has been clinically validated for solid tumors.
Three waves of mouse models have been produced recently (bone marrow transplantation, transgenic and targeted knock-in), which have facilitated the understanding of the molecular pathogenesis of JAK2V617F-positive Mprovidingiding potential platforms for designing and validating novel therapies in humans.
Since no PSA outcome measure has been validated in focal therapy yet, the criteria used for defining radiotherapy failure have been used across most of the studies.
